Prelude Therapeutics Inc Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2019 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Prelude Therapeutics Inc quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2019 to Q4 2023.
  • Prelude Therapeutics Inc Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $148M, a 32.9% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $148M +$36.6M +32.9% Dec 31, 2023 10-K 2024-02-15
Q4 2022 $111M +$35.7M +47.3% Dec 31, 2022 10-K 2024-02-15
Q4 2021 $75.4M +$42.5M +129% Dec 31, 2021 10-K 2023-03-15
Q4 2020 $32.9M +$17.5M +114% Dec 31, 2020 10-K 2022-03-17
Q4 2019 $15.4M Dec 31, 2019 10-K 2021-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.